A novel muscle cramp scale (MCS) in amyotrophic lateral sclerosis (ALS)

Hiroshi Mitsumoto, Codruta Chiuzan, Madison Gilmore, Yuan Zhang, Camila Ibagon, Brittany McHale, Jonathan Hupf, Bjorn Oskarsson

Research output: Contribution to journalArticle

Abstract

Objective: To develop a novel muscle cramp scale (MCS) to assess frequency, severity and clinically meaningful information related to cramps among patients with amyotrophic lateral sclerosis (ALS). Methods: This new scale comprises four 5-point subdomains: (1) triggering factors, (2) frequency, (3) location, (4) severity, and (5) the degree to which cramps affect overall daily living. Thirty patients with ALS, who experienced at least 5 cramps per week, participated in a randomized test-retest study. An additional 26 patients participated in a second study assessing cramp changes over 4 weeks using the MCS and a detailed cramp diary. Results: To establish internal reliability of the scale, a Cronbach’s coefficient value of 0.75 or higher was considered acceptable. Test/retest evaluations comparing in-person and telephone administration were assessed using paired t-tests and Cohen’s kappa statistics. Non-significant differences were identified, and the results revealed moderate to high agreement for each item (range 0.60 to 0.95, p < 0.0001). Scale construct validity against the cramp diary was acceptable. There were essentially no significant mean differences in muscle cramps over 4 weeks measured using the MCS and diary, respectively. Conclusions: The MCS is a valid, simple, and quick measure for the assessment of muscle cramps in patients with ALS. It can be reliably administered either in person or by telephone and provides richer information than the routinely utilized cramp diary.

Fingerprint

Muscle Cramp
Amyotrophic Lateral Sclerosis
Telephone

Keywords

  • ALS
  • assessment measure
  • muscle cramp scale
  • muscle cramps
  • test-retest

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

A novel muscle cramp scale (MCS) in amyotrophic lateral sclerosis (ALS). / Mitsumoto, Hiroshi; Chiuzan, Codruta; Gilmore, Madison; Zhang, Yuan; Ibagon, Camila; McHale, Brittany; Hupf, Jonathan; Oskarsson, Bjorn.

In: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 01.01.2019.

Research output: Contribution to journalArticle

Mitsumoto, Hiroshi ; Chiuzan, Codruta ; Gilmore, Madison ; Zhang, Yuan ; Ibagon, Camila ; McHale, Brittany ; Hupf, Jonathan ; Oskarsson, Bjorn. / A novel muscle cramp scale (MCS) in amyotrophic lateral sclerosis (ALS). In: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2019.
@article{69e84f4b86614298be885e84430bf30d,
title = "A novel muscle cramp scale (MCS) in amyotrophic lateral sclerosis (ALS)",
abstract = "Objective: To develop a novel muscle cramp scale (MCS) to assess frequency, severity and clinically meaningful information related to cramps among patients with amyotrophic lateral sclerosis (ALS). Methods: This new scale comprises four 5-point subdomains: (1) triggering factors, (2) frequency, (3) location, (4) severity, and (5) the degree to which cramps affect overall daily living. Thirty patients with ALS, who experienced at least 5 cramps per week, participated in a randomized test-retest study. An additional 26 patients participated in a second study assessing cramp changes over 4 weeks using the MCS and a detailed cramp diary. Results: To establish internal reliability of the scale, a Cronbach’s coefficient value of 0.75 or higher was considered acceptable. Test/retest evaluations comparing in-person and telephone administration were assessed using paired t-tests and Cohen’s kappa statistics. Non-significant differences were identified, and the results revealed moderate to high agreement for each item (range 0.60 to 0.95, p < 0.0001). Scale construct validity against the cramp diary was acceptable. There were essentially no significant mean differences in muscle cramps over 4 weeks measured using the MCS and diary, respectively. Conclusions: The MCS is a valid, simple, and quick measure for the assessment of muscle cramps in patients with ALS. It can be reliably administered either in person or by telephone and provides richer information than the routinely utilized cramp diary.",
keywords = "ALS, assessment measure, muscle cramp scale, muscle cramps, test-retest",
author = "Hiroshi Mitsumoto and Codruta Chiuzan and Madison Gilmore and Yuan Zhang and Camila Ibagon and Brittany McHale and Jonathan Hupf and Bjorn Oskarsson",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/21678421.2019.1603310",
language = "English (US)",
journal = "Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration",
issn = "2167-8421",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - A novel muscle cramp scale (MCS) in amyotrophic lateral sclerosis (ALS)

AU - Mitsumoto, Hiroshi

AU - Chiuzan, Codruta

AU - Gilmore, Madison

AU - Zhang, Yuan

AU - Ibagon, Camila

AU - McHale, Brittany

AU - Hupf, Jonathan

AU - Oskarsson, Bjorn

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: To develop a novel muscle cramp scale (MCS) to assess frequency, severity and clinically meaningful information related to cramps among patients with amyotrophic lateral sclerosis (ALS). Methods: This new scale comprises four 5-point subdomains: (1) triggering factors, (2) frequency, (3) location, (4) severity, and (5) the degree to which cramps affect overall daily living. Thirty patients with ALS, who experienced at least 5 cramps per week, participated in a randomized test-retest study. An additional 26 patients participated in a second study assessing cramp changes over 4 weeks using the MCS and a detailed cramp diary. Results: To establish internal reliability of the scale, a Cronbach’s coefficient value of 0.75 or higher was considered acceptable. Test/retest evaluations comparing in-person and telephone administration were assessed using paired t-tests and Cohen’s kappa statistics. Non-significant differences were identified, and the results revealed moderate to high agreement for each item (range 0.60 to 0.95, p < 0.0001). Scale construct validity against the cramp diary was acceptable. There were essentially no significant mean differences in muscle cramps over 4 weeks measured using the MCS and diary, respectively. Conclusions: The MCS is a valid, simple, and quick measure for the assessment of muscle cramps in patients with ALS. It can be reliably administered either in person or by telephone and provides richer information than the routinely utilized cramp diary.

AB - Objective: To develop a novel muscle cramp scale (MCS) to assess frequency, severity and clinically meaningful information related to cramps among patients with amyotrophic lateral sclerosis (ALS). Methods: This new scale comprises four 5-point subdomains: (1) triggering factors, (2) frequency, (3) location, (4) severity, and (5) the degree to which cramps affect overall daily living. Thirty patients with ALS, who experienced at least 5 cramps per week, participated in a randomized test-retest study. An additional 26 patients participated in a second study assessing cramp changes over 4 weeks using the MCS and a detailed cramp diary. Results: To establish internal reliability of the scale, a Cronbach’s coefficient value of 0.75 or higher was considered acceptable. Test/retest evaluations comparing in-person and telephone administration were assessed using paired t-tests and Cohen’s kappa statistics. Non-significant differences were identified, and the results revealed moderate to high agreement for each item (range 0.60 to 0.95, p < 0.0001). Scale construct validity against the cramp diary was acceptable. There were essentially no significant mean differences in muscle cramps over 4 weeks measured using the MCS and diary, respectively. Conclusions: The MCS is a valid, simple, and quick measure for the assessment of muscle cramps in patients with ALS. It can be reliably administered either in person or by telephone and provides richer information than the routinely utilized cramp diary.

KW - ALS

KW - assessment measure

KW - muscle cramp scale

KW - muscle cramps

KW - test-retest

UR - http://www.scopus.com/inward/record.url?scp=85064705663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064705663&partnerID=8YFLogxK

U2 - 10.1080/21678421.2019.1603310

DO - 10.1080/21678421.2019.1603310

M3 - Article

JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

SN - 2167-8421

ER -